- Lobbying
- Lobbying by Spectrum Pharmaceuticals, Inc
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Jeffrey Mortier | Prof Staff on E&C Cmte, LA Rep Whitfield and Intern Devin Nunes |
Sarah Walter | Former Legislative Director/Chief Counsel, Sen. John Breaux |
Jeffery MacKinnon | LD & LA Rep. Joe Barton (RTexas) |
Jeff MacKinnon | LD & LA Rep. Joe Barton (RTexas) |
Jeffery Mortier | Prof Staff on E&C Cmte LA Rep Whitfield and Intern Devin Nunes |
J. Daniel Walsh | LD Rep. Wayne Gilchrest and LA Rep. Jack Buechner |
Edward Whitfield | U.S. Representative (21 yrs.) |
Kristen O'Neill | Health Policy Advisory, LA, Staff Assistant Gene Greene (DTX) Staff Assistant GK Butterfield (D-NC) |
Dylan Moore | Intern/Staff Assistant, Speaker John Boehner (OH-8); Legislative Assistant/Legislative Director/Deputy Chief of Staff, Rep. Larry Bucshon (IN-8) Intern/Staff Assistant, Speaker John Boehner (OH-8); Legislative Assistant/Legislative Director/Deputy Chief of Staff, Rep. Larry Bucshon (IN-8); Intern, Rep. Mike Turner (OH-10) |
Jody Gale | n/a |
William Krieger | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Registration
Issue(s) they said they’d lobby about: Issues relating to lung cancer care.
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate